Document:

exv10w5

Exhibit 10.5

DEVELOPERS DIVERSIFIED REALTY CORPORATION

VALUE SHARING EQUITY PROGRAM

     This Developers Diversified Realty Corporation Value Sharing Equity Program (as may be
amended, modified or supplemented from time to time, the “Program”) is established as of July 29,
2009, by Developers Diversified Realty Corporation, an Ohio corporation (the “Company”).

     The Program is designed to allow the Company to reward its officers and other key employees
for successful efforts in helping the Company achieve superior financial performance, as measured
by increases in the Company’s adjusted market capitalization over pre-established periods of time.
Effective as of the date first written above (the “Effective Date”), the Program is hereby
established on the following terms and subject to the following conditions:

     1. Operation Under the Equity Plan. The Program is adopted to operate pursuant to the
Equity Plan and is subject to the terms and conditions set forth herein and in the Equity Plan. In
the event of any inconsistency between the Equity Plan and the Program, the terms and conditions
set forth in the Equity Plan shall control.

     2. Administration.

          (a) The Program will be administered by the Committee. The Committee shall have full power to
interpret and administer the Program.

          (b) The Committee shall have the authority to adopt, alter and repeal such rules, guidelines
and practices governing the Program as it shall, from time to time, deem advisable; to interpret
the terms and provisions of the Program and any Award issued under the Program (and any agreements
relating thereto); to direct Eligible Employees or other advisors to prepare such materials or
perform such analyses as the Committee deems necessary or appropriate; and otherwise to supervise
the administration of the Program.

          (c) Any interpretation or administration of the Program by the Committee, and all actions and
determinations of the Committee, shall be final, binding and conclusive on the Company, its
shareholders, subsidiaries, affiliates, all Participants and Eligible Employees, their respective
legal representatives, successors and assigns, and all persons claiming under or through any of
them. No member of the Board or of the Committee shall incur any liability for any action taken or
omitted, or any determination made, in good faith in connection with the Program.

     3. Definitions. Capitalized terms used herein without definitions shall have the
meanings given to those terms in the 2008 Equity Plan. In addition, as used herein:

     “2008 Equity Plan” means the Amended and Restated 2008 Developers Diversified Realty
Corporation Equity-Based Award Plan, as amended and restated (as may be amended, modified or
supplemented from time to time).

1

 

     “Additional Common Shares” means, for each applicable Measurement Period, the
aggregate number of Common Shares equal to the excess, if any, of (a) the Ending Shares Outstanding
minus (b) the Starting Shares Outstanding; provided, that the number of Additional Common
Shares will not be less than zero.

     “Award” means an Other Share-Based Award that entitles the Participant to earn Award
Shares as determined in accordance with the terms and provisions of the Program.

     “Award Shares” means, for each applicable Measurement Period, the number of Common
Shares earned by a Participant for such Measurement Period pursuant to an Other Share-Based Award,
which Award Shares shall be subject to the additional time-based vesting requirements provided in
Section 8 hereof.

     “Cash Payments” has the meaning set forth in Section 8(a) hereof.

     “Cause” means, unless otherwise provided by the Committee (in order of applicability)
(a) “Cause” as defined in any Individual Agreement to which the Participant is a party, or (b) if
there is no such Individual Agreement or if it does not define Cause: (i) conviction of the
Participant for committing a felony under federal law or in the law of the state in which such
action occurred, (ii) dishonesty in the course of fulfilling the Participant’s employment duties,
(iii) willful and deliberate failure on the part of the Participant to perform the Participant’s
employment duties in any material respect, or (iv) prior to a Change in Control, such other events
as shall be determined by the Committee. The Committee shall, unless otherwise provided in an
Individual Agreement with the Participant, have the sole discretion to determine whether “Cause”
exists, and its determination shall be final.

     “Change in Control” means the occurrence of any of the following:

     (a) consummation of a consolidation or merger in which the Company is not the surviving
corporation, the sale of substantially all of the assets of the Company, or the liquidation
or dissolution of the Company;

     (b) any person or other entity (other than the Company or a subsidiary or any Company
employee benefit plan (including any trustee of any such plan acting in its capacity as
trustee)) purchases any Common Shares (or securities convertible into Common Shares)
pursuant to a tender or exchange offer without the prior consent of the Board, or becomes
the beneficial owner of securities of the Company representing 30% or more of the voting
power of the Company’s outstanding securities without the prior consent of the Board; or

     (c) during any two-year period, individuals who at the beginning of such period
constitute the entire Board cease to constitute a majority of the Board; provided,
that any person becoming a director of the Company during such two-year period whose
election, or nomination for election by the Company’s shareholders, was approved by a vote
of at least two-thirds of the directors who at the beginning of such period constituted the
entire Board (either by a specific vote or by approval of the Company’s proxy statement in
which such person is named as a nominee of the Company for director), but excluding for this
purpose any person whose initial assumption of office as a director of

2

 

the Company occurs as a result of either an actual or threatened election contest with
respect to the election or removal of directors of the Company or other actual or threatened
solicitation of proxies or consents by or on behalf of an individual, the corporation,
partnership, group, associate or other entity or person other than the Board, shall be, for
purposes of this definition, considered as though such person was a member of the Board at
the beginning of such period.

     “Change in Control Measurement Date” means the date upon which a Change in Control
first occurs.

     “Common Share” means a common share, par value $0.10 per share, of the Company.

     “Company” has the meaning set forth in the preamble hereof.

     “Disabled.” A Participant shall be considered Disabled if the Participant has
suffered a Disability.

     “Effective Date” has the meaning set forth in the preamble hereof.

     “Ending Share Price” means the average Share Price for a Common Share for the
five-trading-day period ending on the applicable Measurement Date.

     “Ending Shares Outstanding” means the aggregate number of Common Shares issued and
outstanding, plus the aggregate number of Common Shares for which the OP Units are then
exchangeable, as of the applicable Measurement Date.

     “Eligible Employees” means the employees of the Company.

     “Equity Plan” means, unless otherwise determined by the Committee from time to time,
the equity-based award plan most recently adopted by the Company among the 2008 Equity Plan and the
Other Equity-Based Award Plans under which the Company may grant equity-based performance awards
such as Other Share-Based Awards to employees of the Company.

     “Equity Plan Limit” means the aggregate number of Common Shares available from time to
time for issuance under the Equity Plan.

     “Equity Raised” means an amount equal to the sum of the aggregate value received by
the Company during the period between the Effective Date through and including the applicable
Measurement Date pursuant to (a) the issuance of Additional Common Shares, (b) the exercise of any
warrants representing the right to purchase Common Shares and (c) the conversion of any Company
convertible debt into Company equity (with such Company convertible debt calculated for purposes of
this definition at face value).

     “Equity Repurchased” means the aggregate amount paid by the Company during the period
between the Effective Date through and including the applicable Measurement Date for the repurchase
of Common Shares by the Company.

     “Fifth Measurement Date” means July 31, 2012.

3

 

     “Fifth Measurement Period” has the meaning set forth in the definition of Measurement
Period.

     “Final Measurement Date” means December 31, 2012.

     “Final Measurement Period” has the meaning set forth in the definition of Measurement
Period.

     “First Measurement Date” means July 31, 2010.

     “First Measurement Period” has the meaning set forth in the definition of Measurement
Period.

     “Fourth Measurement Date” means January 31, 2012.

     “Fourth Measurement Period” has the meaning set forth in the definition of Measurement
Period.

     “Gross Award Shares” means, for each applicable Measurement Period, a number of Award
Shares (rounded up to the nearest whole number of Award Shares) equal to the quotient of (a) the
Participant’s Share of Value Created divided by (b) the Ending Share Price on the applicable
Measurement Date for such Measurement Period.

     “Individual Agreement” means an employment or similar agreement between a Participant
and the Company.

     “Initial Market Capitalization” means a value equal to the product of (a) the Starting
Shares Outstanding multiplied by (b) the Starting Share Price.

     “Market Capitalization” means, with respect to an applicable Measurement Date, a value
equal to the product of (a) the Ending Shares Outstanding multiplied by (b) the Ending Share Price.

     “Measurement Date” means, for each applicable Measurement Period, the earlier of the
Change in Control Measurement Date or, as applicable, (a) the First Measurement Date, (b) the
Second Measurement Date, (c) the Third Measurement Date, (d) the Fourth Measurement Date, (e) the
Fifth Measurement Date, or (f) the Final Measurement Date.

     “Measurement Period” means each of the following periods: (a) the period commencing
on the Effective Date and ending on the First Measurement Date (or the Change in Control
Measurement Date, if applicable) (the “First Measurement Period”); (b) the period commencing on the
first day immediately subsequent to the First Measurement Date and ending on the Second Measurement
Date (or the Change in Control Measurement Date, if applicable) (the “Second Measurement Period”);
(c) the period commencing on the first day immediately subsequent to the Second Measurement Date
and ending on the Third Measurement Date (or the Change in Control Measurement Date, if applicable)
(the “Third Measurement Period”); (d) the period commencing on the first day immediately subsequent
to the Third Measurement Date and ending on the Fourth Measurement Date (or the Change in Control
Measurement Date, if applicable)

4

 

(the “Fourth Measurement Period”); (e) the period commencing on the first day immediately
subsequent to the Fourth Measurement Date and ending on the Fifth Measurement Date (or the Change
in Control Measurement Date, if applicable) (the “Fifth Measurement Period”); and (f) the period
commencing on the first day immediately subsequent to the Fifth Measurement Date and ending on the
Final Measurement Date (or the Change in Control Measurement Date, if applicable) (the “Final
Measurement Period”).

     “Notice of Grant” means an agreement between the Company and a Participant
substantially in the form of Exhibit B attached hereto, with such other terms and
provisions as the Committee may determine from time to time.

     “OP Units” means the operating partnership minority interests in the Company.

     “Other Equity-Based Award Plans” means any equity-based award plans (other than the
2008 Equity Plan) maintained by the Company from time to time.

     “Participant” means an Eligible Employee determined by the Committee to participate
under the Program.

     “Participant’s Share of Value Created” means: (a) for the First Measurement Period, a
value equal to the product of (1) Value Created and (2) two-sevenths of the Participant’s Value
Sharing Opportunity; (b) for the Second Measurement Period, a value equal to the product of (1)
Value Created and (2) three-sevenths of the Participant’s Value Sharing Opportunity; (c) for the
Third Measurement Period, a value equal to the product of (1) Value Created and (2) four-sevenths
of the Participant’s Value Sharing Opportunity; (d) for the Fourth Measurement Period, a value
equal to the product of (1) Value Created and (2) five-sevenths of the Participant’s Value Sharing
Opportunity; (e) for the Fifth Measurement Period, a value equal to the product of (1) Value
Created and (2) six-sevenths of the Participant’s Value Sharing Opportunity; and (f) for the Final
Measurement Period, the Participant’s Value Sharing Opportunity.

     “Pro Rata Gross Award Shares” means, for each applicable Measurement Period, a number
of Award Shares equal to the product of (a)(i) the Gross Award Shares minus (ii) the number of
Award Shares, if any, previously earned by the Participant under the Program, multiplied by (b) a
fraction, the numerator of which equals the number of days in the Measurement Period through and
including the date of the Participant’s death or Disability or the date on which the Participant’s
employment with the Company is terminated without Cause, as applicable, and the denominator of
which equals the total number of days in the Measurement Period.

     “Program” has the meaning set forth in the preamble hereof.

     “Second Measurement Date” means January 31, 2011.

     “Second Measurement Period” has the meaning set forth in the definition of Measurement
Period.

     “Share Price” means, as of a given date (in order of applicability): (a) the closing
price of a Common Share on the principal exchange on which the Common Shares are then trading, if

5

 

any, on such date, or if Common Shares were not traded on such date, then on the next
preceding trading day during which a sale occurred; (b) if Common Shares are not then traded on an
exchange, the mean between the closing representative bid and asked prices for Common Shares on
such date as reported by a national quotation system; (c) if Common Shares are not traded on an
exchange and not quoted on a national quotation system, the mean between the closing bid and asked
prices for Common Shares, on such date, as determined in good faith by the Committee; or (d) if
Common Shares are not publicly traded, the fair market value established by the Committee acting in
good faith and in accordance with the applicable requirements of Code Section 409A and the
regulations promulgated thereunder.

     “Starting Shares Outstanding” means the aggregate number of Common Shares issued and
outstanding, plus the aggregate number of Common Shares for which the OP Units are then
exchangeable, as of the Effective Date.

     “Starting Share Price” means the greater of (a) the average closing price of a Common
Share as reported on the New York Stock Exchange over the 20 trading days ending on the Effective
Date and (b) the closing price of a Common Share as reported on the New York Stock Exchange on the
Effective Date.

     “Third Measurement Date” means July 31, 2011.

     “Third Measurement Period” has the meaning set forth in the definition of Measurement
Period.

     “Undelivered Award Shares” has the meaning set forth in Section 8(a) hereof.

     “Value Created” means, for each applicable Measurement Period, an aggregate amount
equal to (a) the Market Capitalization minus (b) the Initial Market Capitalization minus (c) the
Equity Raised (if, during any Measurement Period, the Company issues Additional Common Shares) plus
(d) the Equity Repurchased (if, during any Measurement Period, the Company repurchases Common
Shares).

     “Value Sharing Opportunity” means a percentage established for each Participant from
time to time by the Committee under the Program. As of the Effective Date, the aggregate amount of
the Value Sharing Opportunities equals 2.8743%.

     “Vested Undelivered Award Shares” has the meaning set forth in Section 8(b)
hereof.

     “Vesting Schedule” has the meaning set forth in Section 8(b) hereof.

     4. Participants and Value Sharing Opportunities. The Committee has determined that,
as of the Effective Date, the Eligible Employees serving in the positions listed on Exhibit
A shall be Participants and that each Participant shall be awarded the Value Sharing
Opportunity designated on Exhibit A for such Participant, respectively. Any allocation or
reallocation of, and any adjustment to, the Value Sharing Opportunities for the Participants shall
be made at the sole discretion of the Committee; provided, however, that in no
event shall the Committee reduce the Value Sharing Opportunity for any Participant.

6

 

     5. Awards; Notices of Grant. The Committee shall grant each Participant an Award. In
order to participate in the Program and receive an Award, each Participant must execute and deliver
to the Company a Notice of Grant, which Notice of Grant shall constitute the agreement or other
instrument evidencing the Award as required under the Equity Plan. Each Notice of Grant and Award
will be subject to the terms of the Program and the Equity Plan. In no event will an Award result
in Participants being paid out Award Shares in excess of the annual award limit set forth in the
Equity Plan.

     6. Determining Award Shares. With respect to each applicable Measurement Period, each
Participant shall earn a number of Award Shares equal to the excess, if any, of (a) the Gross Award
Shares minus (b) the number of Award Shares, if any, previously earned by the Participant under the
Program; provided, that the number of Award Shares in each case will not be less than zero.

     7. Effect of Certain Events During a Measurement Period. For each Measurement Period,
if any of the following events occurs during the Measurement Period, then, with respect to such
Measurement Period, Participants shall not earn Award Shares pursuant to Section 6 hereof,
but shall instead earn a number of Award Shares as determined pursuant to this Section 7 as
follows:

          (a) If, during the Measurement Period, a Participant shall die or become Disabled, or the
Participant’s employment with the Company is terminated by the Company without Cause, then (i) the
Participant shall earn a number of Award Shares equal to the Pro Rata Gross Award Shares;
provided, that the number of Pro Rata Gross Award Shares will not be less than zero, and
(ii) the Participant shall immediately, as of the date of such death, Disability or termination of
employment, forfeit any and all rights to receive Award Shares with respect to any and all
subsequent Measurement Periods under the Program.

          (b) If, during the Measurement Period, a Participant’s employment with the Company is
terminated for Cause or the Participant voluntarily terminates his or her employment with the
Company for any reason, then (i) the Participant shall immediately, as of the date of such
termination of employment, forfeit any and all rights to earn Award Shares with respect to such
Measurement Period and any and all subsequent Measurement Periods under the Program, and (ii) any
and all rights the Participant had, or may have had, under the Program will immediately, as of the
date of such termination of employment, be forfeited without further action.

          (c) If, during the Measurement Period, a Change in Control occurs, then (i) the Participant
shall earn a number of Award Shares equal to the excess, if any, of (a) the Gross Award Shares
minus (b) the number of Award Shares, if any, previously earned by the Participant under the
Program; provided, that the number of Award Shares in each case will not be less than zero,
and (ii) all Participants shall immediately, as of the date of such Change in Control, forfeit any
and all rights to earn any Award Shares with respect to any and all subsequent Measurement Periods
under the Program.

     8. Payment; Additional Time-Based Vesting Requirements.

7

 

          (a) The Company will grant to each Participant (or to the estate, guardian or beneficiary of
the Participant, as the case may be) any Award Shares earned by the Participant pursuant to an
Award as soon as reasonably practicable following the applicable Measurement Date, but in no event
later than 30 days after the applicable Measurement Date; provided, however, that,
as determined by the Committee, to the extent any Participant is prohibited under the Equity Plan
(other than because the grant of such Award Shares would cause the aggregate number of Common
Shares issued by the Company under the Equity Plan to exceed the Equity Plan Limit) or otherwise
from being granted or actually receiving in any particular calendar year any Award Shares
previously earned by the Participant pursuant to an Award (the “Undelivered Award Shares”), such
Undelivered Award Shares will be granted to the Participant (or to the estate, guardian or
beneficiary of the Participant, as the case may be) in the immediately succeeding calendar year not
later than January 15th of such immediately succeeding calendar year; provided
further, that if any grant of Award Shares earned under the Program would cause the
aggregate number of Common Shares issued by the Company under the Equity Plan to exceed the Equity
Plan Limit, then each Participant (or the estate, guardian or beneficiary of the Participant, as
the case may be), as applicable, shall be entitled to cash payments (“Cash Payments”) from the
Company in an aggregate amount equal to the product of (i) the Share Price on the applicable
Measurement Date multiplied by (ii) the number of Award Shares earned by the Participant the
granting of which would cause the aggregate number of Common Shares issued by the Company under the
Equity Plan to exceed the Equity Plan Limit, which Cash Payments will be paid by the Company
according to the applicable Vesting Schedule and other vesting provisions provided in this
Section 8 as if such Cash Payments were Award Shares being granted pursuant to this
Section 8, but in all cases subject to the Committee’s ability to again pay Participants in
Award Shares instead of Cash Payments if and when, as determined by the Committee, grants of Award
Shares earned under the Program would no longer cause the aggregate number of Common Shares issued
by the Company under the Equity Plan to exceed the Equity Plan Limit.

          (b) Unless otherwise determined by the Committee at the time an Award is granted, any Award
Shares earned by a Participant under the Program and granted pursuant to Section 8(a)
hereof, and any Undelivered Award Shares to be granted pursuant to Section 8(a) hereof,
will be subject to the following additional time-based vesting requirements: (i) such Award Shares
will vest in 20% annual increments beginning on the date of grant of the Award Shares and on each
of the first four anniversaries of the date of grant of the Award Shares (the “Vesting Schedule”);
and (ii) such Undelivered Award Shares will vest according to the same Vesting Schedule that would
have been applicable had such Undelivered Award Shares been awarded as Award Shares pursuant to
Section 8(a) hereof; provided, that to the extent that any portion of the
Undelivered Award Shares would have vested according to the applicable Vesting Schedule prior to or
as of the date on which such Undelivered Award Shares are actually granted pursuant to Section
8(a) hereof (the “Vested Undelivered Award Shares”), such Vested Undelivered Award Shares will
be immediately vested when the Vested Undelivered Award Shares are actually granted pursuant to
Section 8(a) hereof; provided further, that to the extent that any Award
Shares or Undelivered Award Shares have been earned as a result of the Participant’s death or
Disability pursuant to Section 7(a) hereof, such Award Shares or Undelivered Award Shares
shall not be subject to the additional time-based vesting requirements described in this
Section 8(b).

8

 

          (c) During the Vesting Schedule, the Participant shall not be permitted to sell, transfer,
pledge, assign or otherwise encumber any Award Shares, Cash Payments or Undelivered Award Shares
that remain unvested, and the Award Shares, Cash Payments and Undelivered Award Shares that remain
unvested will also remain subject to forfeiture. Unless otherwise determined by the Committee, if
a Participant’s employment with the Company terminates by reason of death or due to the Participant
becoming Disabled during the Vesting Schedule, (i) any unvested Award Shares held by the
Participant (or unvested Cash Payments) will be immediately vested (and any applicable restrictions
will lapse), and (ii) all Undelivered Award Shares will be immediately vested (and any applicable
restrictions will lapse) when such Undelivered Award Shares are actually granted pursuant to
Section 8(a) hereof. Further, unless otherwise determined by the Committee or as provided
for in an Individual Agreement, if a Participant’s employment with the Company is terminated
without Cause during the Vesting Schedule, any unvested Award Shares held by the Participant (or
unvested Cash Payments) and any Undelivered Award Shares shall not be forfeited by the Participant,
but instead such unvested Award Shares (or unvested Cash Payments) and Undelivered Award Shares
shall remain outstanding and shall continue to vest according to the Vesting Schedule described in
Section 8(b) hereof. Unless otherwise determined by the Committee or as provided for in an
Individual Agreement, if a Participant’s employment with the Company terminates during the Vesting
Schedule for any reason other than due to death, due to the Participant becoming Disabled or due to
the Participant’s employment with the Company being terminated without Cause during the Vesting
Schedule, (A) any unvested Award Shares held by the Participant (or unvested Cash Payments) at the
time of such termination will thereupon be forfeited, and (B) any Undelivered Award Shares other
than Vested Undelivered Award Shares will thereupon be forfeited.

          (d) Except to the extent provided by Section 409A of the Code and as permitted by the Company,
no Common Shares may be issued to the Participant and no cash payment may be made to the
Participant at a time earlier than otherwise expressly provided in the Program.

          (e) The Company’s obligations to any Participant with respect to his or her Award will be
satisfied in full upon the grant of any earned Award Shares (or Undelivered Award Shares, if
applicable) corresponding to the Award or upon the payment of cash to the Participant pursuant to
Section 8(a) hereof.

     9. Shareholder Rights and Restrictions.

          (a) No Participant shall have any rights as a shareholder of the Company (including, without
limitation, the right to receive dividends or voting rights) with respect to an Award or any Award
Shares until any earned Award Shares (or Undelivered Award Shares, if applicable) are issued.

          (b) Award Shares and Undelivered Award Shares shall be subject to the terms and conditions set
forth in the Notice of Grant relating to such Award Shares and Undelivered Award Shares.

9

 

          (c) The obligations of the Company under this Program will be merely that of an unfunded and
unsecured promise of the Company to deliver Award Shares in the future, and the rights of a
Participant will be no greater than that of an unsecured general creditor. No assets of the
Company will be held or set aside as security for the obligations of the Company under this
Program.

     10. Transferability. Awards and unvested Award Shares will not be assignable or
transferable by any Participant; provided, however, that no provision in the
Program will prevent the transfer of an Award or any unvested Award Shares by will or the laws of
descent and distribution in the event of the death of the Participant.

     11. Section 409A of the Code. It is intended that the Program comply with the
provisions of Section 409A of the Code. The Program will be administered in a manner that is
intended to comply with Section 409A of the Code.

     12. Interpretation. Any reference in the Program to Section 409A of the Code will
also include any proposed, temporary or final regulations, or any other guidance, promulgated with
respect to such Section by the U.S. Department of Treasury or the Internal Revenue Service.

     13. No Employment Rights. None of participation in the Program, the grant of any
Award and the delivery of any Award Shares will confer upon any Participant any right with respect
to continuance of employment by the Company.

     14. Severability. In the event that one or more of the provisions of the Program
shall be invalidated for any reason by a court of competent jurisdiction, any provision so
invalidated shall be deemed to be separable from the other provisions hereof, and the remaining
provisions hereof shall continue to be valid and fully enforceable.

     15. Adjustments, Etc. In the event of any (a) any stock dividend, stock split,
combination of shares, recapitalization or other change in the capital structure of the Company,
(b) any merger, consolidation, spin-off, split- off, spin-out, split-up, reorganization, partial or
complete liquidation or other distribution of assets, issuance of rights or warrants to purchase
securities, or (c) any other corporate transaction or event having an effect similar to any of the
foregoing, the Committee shall make such substitutions or adjustments, if any, as are deemed
necessary or equitable in its sole discretion to preserve the intent of this Program and to avoid
any unintended windfalls or hardships with respect to the number or valuation of Awards or Award
Shares.

     16. Taxes. To the extent that the Company is required to withhold federal, state,
local or foreign taxes in connection with any payment made or benefit realized by a Participant or
other person under the Program, and the amounts available to the Company for such withholding are
insufficient, it will be a condition to the receipt of such payment or the realization of such
benefit that the Participant or such other person make arrangements satisfactory to the Company for
payment of the balance of such taxes required to be withheld, which arrangements (in the discretion
of the Committee) may include relinquishment of a portion of such benefit. Notwithstanding the
foregoing, when a Participant is required to pay the Company an amount required to be withheld
under applicable income and employment tax laws, the Participant may

10

 

elect to satisfy the obligation, in whole or in part, by electing to have withheld, from the
Award Shares required to be delivered to the Participant, Award Shares having a value equal to the
amount required to be withheld, or by delivering to the Company Common Shares held by such
Participant. The Award Shares or Common Shares used for tax withholding will be valued at an
amount equal to the market value per share of such Award Shares or Common Shares on the date the
applicable amount is to be included in the Participant’s income. In no event will the market value
per share of the Award Shares to be withheld pursuant to this Section 16 to satisfy
applicable withholding taxes exceed the minimum amount of taxes required to be withheld.

     17. Governing Law. The laws of the State of Ohio will govern this Program and all
matters related hereto. If any Participant or the Company institutes a suit or other legal
proceedings, whether in law or equity with respect to this Program, the Company and such
Participant irrevocably consents to the jurisdiction of the Common Pleas Court of the State of Ohio
(Cuyahoga County) or the United States District Court for the Northern District of Ohio.

     18. Amendments, Etc. The Committee may amend the terms of any Award under the Program
prospectively or retroactively, but subject to Section 15 hereof, no such amendment shall
impair the rights of any Participant without his or her consent. The Program, the Equity Plan and
the Notices of Grant contain the entire agreement between the Company and the Participants relating
to the Program.

[signature on following page]

11

 

	 	 	 	 	 
	 	DEVELOPERS DIVERSIFIED REALTY 

CORPORATION

 	 
	 	By:  	/s/ Robert H. Gidel
 	 
	 	 	Robert H. Gidel 	 
	 	 	Chairman of the Executive Compensation
Committee 	 

12

 

EXHIBIT A

	 	 	 
	Participants	 	Value Sharing Opportunities
	 
	 	 
	Chairman & Chief Executive Officer (1 total)

	 	0.7250% (72.50 basis points)
	President & Chief Operating Officer (1 total)

	 	0.5800% (58.00 basis points)
	Senior Executive Vice Presidents (2 total)

	 	0.1300% (13.00 basis points)
	Executive Vice Presidents (5 total)

	 	0.0725% (7.25 basis points)
	Senior Vice Presidents (17 total)

	 	0.0400% (4.00 basis points)
	Vice Presidents (23 total)

	 	0.0116% (1.16 basis points)

 

 

EXHIBIT B

DEVELOPERS DIVERSIFIED REALTY CORPORATION

NOTICE OF GRANT UNDER THE VALUE SHARING EQUITY PROGRAM

     The undersigned individual (the “Participant”) has been granted the following Award under the
Developers Diversified Realty Corporation Value Sharing Equity Program (the “Program”):

	 	 	 
	Name of Participant:

	 	__________________________________________
	 
	 	 
	Award Grant Date:

	 	__________________________________________
	 
	 	 
	Measurement Periods in which 

Participant will participate:

	 	__________________________________________
	 

	 	__________________________________________
	 
	 	 
	Value Sharing Opportunity:

	 	__________________________________________
	 
	 	 
	Vesting Schedule:

	 	__________________________________________
	 

	 	__________________________________________
	 

	 	__________________________________________

     By the Participant’s signature and the signature of the Company representative below, the
Participant and the Company agree that this Award is granted under and governed by the terms and
conditions of the Program (the provisions of which are incorporated herein by reference) and the
Equity Plan, copies of both of which are attached to and made a part of this document, which
document shall constitute the agreement or other instrument evidencing the Award as required under
the Equity Plan. The Participant shall have such rights regarding his or her election to settle
any tax withholding obligations with Award Shares or Common Shares as are described in Section 16
of the Program. Capitalized terms used in this document without definitions shall have the
meanings given to those terms in the Program.

	 	 	 
	PARTICIPANT

	 	DEVELOPERS DIVERSIFIED

REALTY CORPORATION
	 
	 	 
	 
	 	 
	 

Participant’s Signature

	 	 

	 

	 	By:
 

	 
	 	 
	 

Participant’s Printed Name

	 	Its:exv10w5

Exhibit 10.5

Confidential
Materials omitted and filed separately with the 
Securities and Exchange Commission. Asterisks denote omissions.

Amendment 1

BISx Development, Purchase and License Agreement

This Amendment 1 to the BISx Development, Purchase and License Agreement dated the 28th
day of January, 2004 (the “Agreement”), by and between Aspect Medical Systems, Inc. (“Aspect”) and
Draeger Medical Systems, Inc. (“Draeger”) is made as of
this 26th day of August 2009 (“Amendment
Effective Date”).

WHEREAS, in accordance with Section 25.10 of the Agreement, the Parties desire to amend the
Agreement as set forth herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the undersigned agree as follows:

	 	1.	 	Exhibits
	 
	 	 	 	a) “Exhibit A: Aspect Products and Purchase Prices” is replaced by the attached “Exhibit
A: Aspect Products and Purchase Prices”.
	 
	 	 	 	b) “Exhibit B: Specifications: Aspect BISx Kit” is replaced by the attached “Exhibit B:
Specifications: Aspect BISx KIT”.
	 
	 	 	 	c) “Exhibit C Contact Persons/Addresses” is replaced by the attached “Exhibit C Contact
Persons/Addresses”
	 
	 	 	 	2. Section 2 of the Agreement will be replaced by the following:

“Aspect’s Bispectral Index” or “BIS” is Aspect’s proprietary processed EEG
parameter that may be used as an aid in monitoring the effects of certain anesthetic
agents.
	 
	 	 	 	“Draeger Patient Monitors” means systems currently installed that have had the
necessary software upgrades to be BIS compatible, as well as the Delta model monitors
currently in production. Draeger Patient Monitors may include future models of Draeger
monitors at Draeger’s choice and discretion.
	 
	 	 	 	“BISx” is the integrated solution of Aspect’s BIS Engine processing technology
and the DSC-XP which can process 2 channels of EEG.
	 
	 	 	 	“BISx4” is the integrated solution of Aspect’s BIS Engine processing
technology and the DSC-XP which can process either 2 or 4 channels of EEG.
	 
	 	 	 	“DSC-XP” is Aspect’s Digital Signal Converter using XP technology; a predecessor
technology to the BISx. The DSC-XP is a small box that is kept close to the patient that
converts the analog EEG signals to digital signals for processing the BIS value.

1/13

 

	 	 	 	“Aspect BISx Kit” is the Aspect components of the Draeger BISx System that are
developed and manufactured by or for Aspect and licensed/sold to Draeger under this
Agreement including the BISx and the Patient Interface Cable (“PIC”) or the BISx4 and the
Four Channel Patient Interface Cable (“PIC4”).
	 
	 	 	 	“Fixed Monitor Cable” is a cable that is semi-permanently attached to the BISx
and connects the BISx to the Draeger Patient Monitor. This cable will be primarily
designed by Aspect with assistance from Draeger and supplied as part of the Aspect BISx
Kit. It can be disconnected from the BISx only by a qualified service person.
	 
	 	 	 	“Detachable Monitor Cable” is a cable that connects the BISx to the Draeger Patient
Monitor. This cable will be primarily designed by Draeger, with assistance from Aspect and
supplied by Draeger or its manufacturer for final assembly with the Aspect BISx Kit.
	 
	 	 	 	“Pod-Com Interface” is a Draeger proprietary interface used to connect external
devices to the Draeger Patient Monitoring Systems.
	 
	 	 	 	“Pod-Com Connector” is the connector that will be integrated into the BISx system
that will allow the Detachable Monitor Cable to plug into the BISx unit.
	 
	 	 	 	“Draeger BISx System” is the combined Aspect BISx Kit and Monitor Cable.
	 
	 	 	 	“Aspect BIS Sensor” means a single use disposable sensor manufactured by Aspect for
use with the Aspect BISx Kit in the OR and ICU that is required to generate Aspect’s
Bispectral Index. These sensors include the BIS Quatro Sensor, the BIS Extend Sensor, the
BIS Bilateral Sensor and the BIS Pediatric Sensor.
	 
	 	 	 	“Aspect BIS Engine” is the predecessor processing unit of the BISx for deriving BIS
data from the raw EEG signal and consists of a PC board and connectors. This component is
used in OEM modules to provide the BIS index on modular patient monitoring systems.
	 
	 	 	 	“Aspect Products” means Aspect BISx Kit and any other product that can be ordered
by Draeger as listed in Exhibit A (Aspect Products and Purchase Prices).
	 
	 	 	 	“Software” means Aspect software programs in binary code form that are designed for
use with the Aspect BISx Kit.
	 
	 	 	 	“Documentation” means the BISx Serial Interface Specification.
	 
	 	 	 	“Party” or “Parties” shall mean Aspect and Draeger each individually or
jointly.
	 
	 	 	 	“Affiliate” shall mean, with respect to either Aspect or Draeger, any other
business entity which, directly or indirectly, controls, is controlled by, or is under
common control with Aspect or Draeger, respectively.

	 	3.	 	Section 4.3 of the Agreement is hereby replaced by the following:

	 	4.3	 	Distribution of Aspect BIS Sensors.
	 
	 	 	 	(a) Global Distribution

2/13

 

	 	 	 	Draeger may sell [**] of Aspect BIS Sensors (either [**]) with each Draeger BISx
System sold to the customer purchasing the corresponding Draeger BISx System.
These sensors are solely for resale to end-users at the time of sale of the Draeger
BISx System.
	 
	 	 	 	Draeger can [**] beyond the effective date of this Addendum [**] with long term
contracts closed prior to [**] and Aspect agrees to honor Draeger sensor purchase
commitments for contracts executed prior to this date by selling directly to the
Draeger central procurement site currently located at Luebeck, Germany.
	 
	 	 	 	Draeger agrees to supply Aspect with a list of customers that have entered into
long-term BIS Sensor purchasing contracts which extend beyond [**] (“Pre-existing
Supply Obligation List”), along with anticipated [**] for the remainder of the
contract time.
	 
	 	 	 	If any dispute arises regarding the status of long-term sensor contracts, Aspect
will have the right to have an independent auditor review the sensor contracts. If
any sales are not aligned with the agreed upon list of pre-existing customers,
Draeger will cease sales to that account and Draeger will retroactively pay Aspect
an [**] for every sensor previously sold outside the Pre-existing Supply
Obligation List. Aspect will [**] current sensor pricing and quantities for
pre-existing supply obligations (per 2004 Agreement, using 2007 sales levels for
determining the appropriate price) in order for Draeger to supply sensors to such
customers until [**] or the end-user chooses to buy directly from Aspect. Draeger
agrees not to renew any long-term BIS Sensor supply contracts currently in place.
	 
	 	 	 	(b) Draeger may purchase Aspect BIS Sensors (Starter Kit of 5 BIS Quatro Sensors or
Starter Kit of 5 BIS Pediatric Sensors) for demonstration purposes. Aspect BIS
Sensors purchased for demonstration use may not be resold to customers.
	 
	 	 	 	(c) Prices

Prices for Aspect BIS Sensors purchased by Draeger hereunder shall be as set forth
in Exhibit A (Aspect Products and Purchase Prices).
	 
	 	 	 	(d) Draeger, or its Affiliates, may continue to sell Aspect BIS Sensors beyond the
date of this Amedment to customers in territories or regions where Aspect has
entered into, or may enter into, distribution agreements with Draeger or its
Affiliates to sell and market Aspect BIS Sensors.

	 	4.	 	Section 5.4 of the Agreement will be replaced by the following:

	 	5.4	 	Installed Base Reporting

3/13

 

	 	 	 	On a [**] basis, Draeger will report the number of BISx Systems installed during
that [**], dates of installation and overall base of BISx Systems by hospital [**]
Draeger, Draeger will then report BISx Systems [**]. This
information will be
[**].

	 	5.	 	Section 6.1 of the Agreement is hereby replaced with the following

	 	6.1	 	Commissions on Sales of Aspect BIS Sensors.
	 
	 	 	 	For each Aspect BIS Sensor sold by Aspect to Draeger customers for use with Draeger
BISx Systems, Aspect shall pay Draeger a commission equal to [**] percent of the
net sales revenue (invoice price after discounts) billed by Aspect for such Aspect
BIS Sensors. Aspect shall pay such commissions to Draeger on a [**] basis. With
such [**] payments, Aspect shall provide to Draeger a list of Draeger customers to
which such sales were made, the number of sensors sold in that [**], and the net
revenue billed for the sale of the sensors by Aspect. This [**] payment shall be
provided to Draeger no later than [**] following the end of each [**]. In the event
that Aspect’s standalone BIS monitors and/or, the BIS modules and/or the BISx
Systems of other manufacturers have also been installed at such sites in addition
to Draeger BISx Systems, Draeger will be entitled to a [**] percent commission only
on BIS Sensor sales intended for use with Draeger BISx Systems. A pro rata
determination will be based on the total number of BIS units of different types
installed at such locations during the period according to Aspect’s installed base
records. To facilitate such calculations, Draeger will be responsible for providing
Aspect with the documentation required in Section 5.4, and Aspect shall be
responsible for providing Draeger with accurate information regarding the total
number of non-Draeger units which have been installed, and are in use, at such
sites. In such situations where information is not available at a hospital level,
it will be calculated at an aggregate regional level. For example, [**] Draeger
commission will be calculated [**]. The information [**].
	 
	 	 	 	The commission amounts above will be reduced on a prorated basis to reflect
customers which continue to purchase from Draeger beyond the effective date of this
addendum with long term contracts closed prior to [**] as defined in Section
4.3(a). For example, if [**]% of Draeger customers continue to purchase from
Draeger through long-term contracts beyond [**], the overall commission will be
reduced by [**]%. As customers transition from Draeger to Aspect during the term
of the agreement, the commission will be increased accordingly. The commission
reduction calculation shall not include sales of Aspect BIS Sensors under, and in
compliance with, distribution agreements as described in Section 4.3(d).

4/13

 

	 	 	 	The commissions described in this Section 6.1 shall be payable for a period of [**]
years after the initial installation of a Draeger BISx System with a Draeger
Patient Monitoring System at the relevant customer site.

	 	6.	 	Section 7.3 of the Agreement is eliminated.
	 
	 	7.	 	Section 22.1 of the Agreement is hereby replaced by the following:

	 	22.1	 	Term and Renewal 

The initial term of this Agreement shall commence on the Effective Date and continue through
December 31st, 2012, unless earlier terminated as provided herein. The term of this
Agreement shall thereafter be renewed automatically for successive twelve (12) month periods,
unless either Party provides written notice of termination to the other Party at least sixty (60)
days prior to expiration of the Agreement.

	 	8.	 	Capitalized terms used, but not defined, herein shall have the meaning ascribed to them in
the Agreement.

	 	9.	 	Except as amended by this Amendment 1, the Agreement shall remain in full force and effect.
After the Amendment Effective Date, every reference in the Agreement or this Amendment 1 to
the “Agreement” shall mean the Agreement as amended by this Amendment 1.

5/13

 

Acceptance of this Amendment 1 is indicated by signatures below.

	 	 	 	 	 	 	 
	Aspect Medical Systems, Inc.	 	Draeger Medical Systems, Inc.
	 
	 	 	 	 	 	 
	By:

	 	/s/ Neal Armstrong
	 	By:
	 	/s/ Bernd Nagel
	 

	 	 
	 	 	 	 
	

	 	Name: Neal Armstrong

Title: Chief Financial Officer
	 	

	 	Name: Bernd Nagel

Title: VP Strategic Sourcing

6/13

 

EXHIBIT A

REVISED ASPECT PRODUCTS AND PURCHASE PRICES

	A)	 	DRAEGER BISx SYSTEMS:

	 	 	 	 	 	 	 
	Aspect Part	 	 	 	Unit of	 	List
	Number	 	Product Description	 	Measure	 	Price
	186-0195-DM

	 	Draeger BISx System with BISx
	 	1 each
	 	[**]
	186-XXXX-DM

	 	Draeger BISx System with BISx4
	 	1 each
	 	[**]

	 	 	 	 	 
	Cumulative Annual	 	 	 	 
	Total Volume (in	 	Draeger BISx	 	Draeger BISx
	units)** (Calendar	 	Systems with BISx*	 	Systems with
	Year)	 	186-0195-DM	 	BISx4*
	[**]

	 	[**]
	 	[**]
	[**]

	 	[**]
	 	[**]
	[**]

	 	[**]
	 	[**]

 

			
	*	 	Pricing assumes the current cost of the Fixed Monitor Cable less $[**] as defined in
Section 7.4(a) of the Agreement.
	 
	**	 	Total calculation includes all Draeger BISx System types (as further described in
Section E below).

C) BIS DISPOSABLE SENSORS

	 	 	 	 	 	 	 	 	 
	Aspect Part	 	Draeger Part	 	 	 	Unit of	 	Draeger
	Number	 	Number	 	Product Description	 	Measure	 	Price
	186-0100*

	 	 	 	BIS Standard Sensor
	 	Box of 25
	 	[**]
	186-0106*

	 	 	 	BIS Quatro Sensor
	 	Box of 25
	 	[**]
	186-0200*

	 	 	 	BIS Pediatric Sensor
	 	Box of 25
	 	[**]
	 
	 	 	 	 	 	 	 	 
	186-0212*

	 	719-0018-00
	 	BIS Bilateral Sensor
	 	Box of 10
	 	[**]

 

			
	*	 	Limit one box of sensors sold upon initial installation of a Draeger BISx System.
	 
	*	 	For the purposes of One Time Tender Offers, Draeger will be allowed to purchase sensors at the
current published International list price (as of July 2, 2009 : [**]) minus a [**]% discount.
Draeger will provide Aspect notification of this occurrence along with Hospital information and
quantities sold.

7/13

 

	 	ii)	 	Demonstration Sensors:

	 	 	 	 	 	 	 	 	 
	Aspect Part	 	Draeger Part	 	 	 	Unit of	 	Draeger
	Number	 	Number	 	Product Description	 	Measure	 	Price
	186-0150

	 	 	 	BIS Quatro Starter Kit
	 	Box of 5
	 	[**]
	186-0206

	 	 	 	BIS Pediatric Starter Kit
	 	Box of 5
	 	[**]

	 	 	 	Demonstration Sensors cannot be resold by Draeger.

	E)	 	CALCULATION OF VOLUME DISCOUNT:
	 
	 	 	For the purpose of calculating the volume discount for a given calendar year, all Draeger BISx
Systems (excluding Aspect Products that are shipped free of charge) will be included in the
total volume discount calculation, e.g. Draeger BISx Systems including both BISx and BISx4
devices.
	 
	 	 	The initial pricing for a given calendar year is based on the total volume of Draeger BISx
Systems purchased in the prior calendar year. For example, if [**] Draeger BISx Systems were
purchased in year 1, the initial volume pricing level for year 2 will be the [**] unit price
level. The Parties agree that, for the period beginning on the Amendment Effective Date and
continuing through December 31, 2008, pricing will start at the [**] unit price level.
	 
	 	 	If a higher volume level of Draeger BISx Systems sales is achieved during a given calendar
year, the price on only those Draeger BISx Systems purchased after achieving the higher volume
level will reflect the price associated with the appropriate volume level achieved. All price
adjustments will apply on a going forward basis only. For example, if midway through year two,
[**] Draeger BISx Systems are purchased, the price on the [**] Draeger BISx System will reflect
the next volume break.
	 
	F)	 	CURRENCY
	 
	 	 	United States Dollars

8/13

 

EXHIBIT B

SPECIFICATIONS: ASPECT BISx KIT

	 	 	 	PRODUCT DESCRIPTION

The Aspect BISx Kit includes a PIC+, BISx Device, and a Host Monitor Cable. The Aspect
BISx kit will here forth be referred to as BISx. The BISx4 Kit includes a 4 channel PIC,
BISx4 Device, and a Host Monitor Cable. The BISx4 kit will here forth be referred to as
BISx4.
	 
	 	 	 	BISx is a device that acquires up to two channels of EEG and computes BIS and other EEG
parameters. BISx4 is a device that acquires up to four channels of EEG and computes BIS
and other EEG parameters. Both the BISx and BISx4 are designed to mate with Aspect’s XP
platform 1 or 2 channel sensors. The BISx4 is designed to additionally interface with
Aspect’s Bilateral sensor, which is required for acquisition of 4 channels of EEG. BISx
and BISx4 have no display or user interface. They plug into a host monitor system for
display of EEG and processed parameters. BISx and BISx4 are designed for use wherever
sedative drugs are administered, including but not limited to the following environments:
Operating rooms, Intensive Care Units, Procedural Sedation, and Clinical Research areas.
	 
	 	 	 	BISx and BISx4 interface to one or more of the following interfaces: standard RS-232
asynchronous interface, RS-232 type asynchronous interface but with TTL 3.3V signal levels,
or Universal Serial Bus (USB) interface. All interface versions also support USB
interfacing for software upgrade and download purposes. BISx and BISx4 can be connected
and disconnected to an already powered up host monitor. The host monitor should
automatically detect its presence and configure it accordingly.

9/13

 

	 	 	 	The BISx connects to a sensor via the Aspect Patient Interface Cable (here forth referred
to as PIC+). The PIC+ is nominally 4.5 ft. long. The PIC+ connection is integral to the
enclosure (no pigtail), and can be detached from the BISx device for service or replacement
without the use of tools. The enclosure is sealed against liquid ingress even when the
PIC+ is detached.
	 
	 	 	 	The BISx4 connects to a sensor via the Aspect 4 channel Patient Interface Cable (here forth
referred to as CM PIC). The CM PIC is nominally 54 inches long. The CM PIC connection is
integral to the enclosure (no pigtail), and can be detached from the BISx4 device for
service or replacement without the use of tools. The enclosure is sealed against liquid
ingress even when the PIC+ is detached.
	 
	 	 	 	The BISx and BISx4 are attached to the host monitoring system via a nominal 9-foot monitor
cable. The host connector of the monitor cable is host system dependent and is the source
of future development with Draeger. The wire is narrow and highly flexible multi-conductor
cable used to supply power from the host monitor to the BISx/BISx4 as well as allow
communication between the devices. Additionally, the inability of the host monitor to
provide the BISx specified power requirements or communication requirements may be
addressed through the inclusion of a circuit which is integral to the host monitor cable.
	 
	 	 	 	The host monitor cable connection to the BISx/BISx4 device is integral to the enclosure (no
pigtail), and may require the use of tools for detachment from the BISx/BISx4 device
enclosure for the purposes of service or replacement. The enclosure is sealed against
liquid ingress only when the monitor cable is attached. There are no adjustable parts
inside the BISx. The cables may be replaced without opening the enclosure.
	 
	 	 	 	The BISx and BISx4 include software which is stored in reprogrammable FLASH memory.
Software upgrades can be accomplished via the serial / USB interface. Each BISx and BISx4
is given a unique serial identifier, allowing for electronic identification and tracking of
every BISx/BISx4.
	 
	 	 	 	
PRELIMINARY TECHNICAL SPECIFICATIONS

(Unless otherwise noted specifications apply to both the BISx and BISx4)
	 
	 	 	 	Physical Specifications

BISx Kit

Size: 95.3 mm (3.75”) diameter x 63.5 mm (2.5”) height

Weight:   approx 8.0 oz without cables

                approx 10.0 oz including PIC+

BISx Integral Cables

Host Monitor Cable: 2.74m (9ft)

Patient Interface Cable (PIC+): 1.4m (4.5 ft)

10/13

 

BISx4 Kit

Size: 95.3 mm (3.75”) diameter x 63.5 mm (2.5”) height

Weight: 227g (8.0 oz) without cables

BISx4 Integral Cables

Host Monitor Cable: 2.74m (9ft)

Patient Interface Cable (CM PIC): 1.4m (4.5 ft)

Safety Specifications

	•	 	The BISx and BISx4 comply with the essential requirements of the Medical Device Directive
93/42/EEC, as well as IEC 60601-1 and IEC 60601-2-26.
	 
	•	 	They are both Type BF applied parts. Both the BISx and BISx4 have internal optical
coupling and an isolation transformer for patient isolation.
	 
	•	 	Both are protected against damage from defibrillation as long as the sensor is not located
between the defibrillator pads and is resistant to artifact from electrosurgery.
	 
	•	 	United States federal law restricts these devices to sale by or on the order of a
physician.
	 
	•	 	BISx, BISx4, and cables are latex free.

Environmental Specifications

Liquid Ingress: IEC 529 IPX4

Temperature

0 to 40 degrees C operating

-40 to 70 degrees C storage

Humidity

10% to 95% non-condensing operating

10% to 95% non-condensing storage

Pressure

480 to 1067 hPa operating (Approx -1250 to 20,000 feet)

116 to 1067 hPa storage (Approx -1250 to 50,000 feet)

Performance Specifications

Measurement Ranges

Bispectral Index (BIS): 0 to 100 unitless scale

Electromyographic Strength (EMG): 25 to 100 dB where 1 μV2=40dB

Signal Quality Index (SQI): 0 to 100%

Suppression Ratio (SR): 0 to 100%

Spectral Edge Frequency (SEF): 0.5 to 30.0 Hz

Total Power: 40 to 100 dB where 1 μV RMS=40dB

Burst Count: 0 to 30

Noise (EEG Waveform) < 0.3 μVRMS (2.0 μV peak-to-peak)

BIS Numeric Update Frequency Once per second

EEG Bandwidth 0.25 to 100 Hz (- 3dB)

Patient Leakage <10uA

11/13

 

12/13

 

EXHIBIT C

CONTACT PERSONS/ADDRESSES

Contact Persons and Responsibilities at Aspect:

	 	 	 	 	 	 	 
	Person	 	Title	 	Responsibility	 	Email
	Bob Cormier

	 	Director,

Sales Operations
	 	Contract
	 	rcormier@aspectms.com
	Ronda Kalis

	 	Product Manager, OEM
	 	Marketing
	 	rkalis@aspectms.com
	Steve Mesrobian

	 	Director, OEM

Engineering
	 	Project Manager
	 	smesrobian@aspectms.com
	Christine Vozella

	 	Senior Director,

RA/QA
	 	Quality and
Regulatory Matters
	 	cvozella@aspectms.com
	James Charest

	 	OEM Engineer
	 	Technical Design

Issues
	 	jcharest@aspectms.com

	 	 	 
	Mailing
Address:

	 	Aspect Medical Systems, Inc.
	 

	 	One Upland Road
	 

	 	Norwood, MA 02062

Contact Persons and Responsibilities at Draeger:

	 	 	 	 	 	 	 
	Person	 	Title	 	Responsibility	 	Email
	 

	 	 	 	Marketing	 	 
	 

	 	 	 	Engineering	 	 
	 

	 	 	 	Contracts	 	 
	 

	 	 	 	Project Management	 	 

	 	 	 
	Mailing
Address:

	 	Draeger Medical Systems, Inc.

6 Tech Drive

Andover, MA 08010

13/13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]